155 related articles for article (PubMed ID: 28199021)
1. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
Elliott JW; Swinbourne F; Parry A; Baines L
J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
3. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
Irie M; Takeuchi Y; Ohtake Y; Suzuki H; Nagata N; Miyoshi T; Kagawa Y; Yamagami T
J Vet Med Sci; 2015 Nov; 77(11):1535-9. PubMed ID: 26074249
[TBL] [Abstract][Full Text] [Related]
7. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
8. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
9. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
10. Successful post-incomplete resection management of gastrointestinal stromal tumor using imatinib based on adenosine triphosphate-based tumor sensitivity assay in a dog.
Woo IS; Kim YR; Kim SW; Choi JY; Yoon HY; Bae K; Yoon KA; Kim JH
Can Vet J; 2024 Jun; 65(6):553-558. PubMed ID: 38827592
[TBL] [Abstract][Full Text] [Related]
11. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
13. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
14. Metastatic gastrointestinal stromal tumors.
Aubin F; Blanke CD
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S9-14. PubMed ID: 21116628
[No Abstract] [Full Text] [Related]
15. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
18. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
20. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Caram MV; Schuetze SM
J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]